J. Goldman & Co LP bought a new position in Stemline Therapeutics, Inc. (NASDAQ:STML) during the fourth quarter, Holdings Channel reports. The institutional investor bought 199,886 shares of the biopharmaceutical company’s stock, valued at approximately $2,139,000. J. Goldman & Co LP owned about 1.12% of Stemline Therapeutics as of its most recent filing with the SEC.
Other institutional investors have also made changes to their positions in the company. Oxford Asset Management acquired a new position in shares of Stemline Therapeutics during the fourth quarter worth $431,000. State Street Corp increased its position in Stemline Therapeutics by 9.2% in the fourth quarter. State Street Corp now owns 251,804 shares of the biopharmaceutical company’s stock valued at $2,694,000 after buying an additional 21,296 shares during the last quarter. Candriam Luxembourg S.C.A. purchased a new position in Stemline Therapeutics during the third quarter valued at approximately $2,783,000. Baker BROS. Advisors LP purchased a new position in Stemline Therapeutics during the third quarter valued at approximately $3,612,000. Finally, Columbus Circle Investors purchased a new position in Stemline Therapeutics during the third quarter valued at approximately $1,577,000. Hedge funds and other institutional investors own 37.76% of the company’s stock.
Shares of Stemline Therapeutics, Inc. (NASDAQ:STML) remained flat at $6.95 during midday trading on Tuesday. 151,910 shares of the company traded hands. Stemline Therapeutics, Inc. has a 12 month low of $3.88 and a 12 month high of $14.60. The firm’s market capitalization is $124.03 million. The company has a 50 day moving average of $10.25 and a 200-day moving average of $10.52.
This news story was reported by sleekmoney and is the sole property of of sleekmoney. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this news story can be accessed at http://sleekmoney.com/j-goldman-co-lp-invests-2139000-in-stemline-therapeutics-inc-stml/1661037.html.
A number of equities research analysts have issued reports on STML shares. Roth Capital reissued a “buy” rating and set a $32.00 target price on shares of Stemline Therapeutics in a report on Wednesday, December 7th. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 price target on shares of Stemline Therapeutics in a report on Monday, December 12th. Wedbush reiterated an “outperform” rating and issued a $15.00 target price on shares of Stemline Therapeutics in a research report on Tuesday, December 6th. Jefferies Group LLC set a $23.00 target price on shares of Stemline Therapeutics and gave the stock a “buy” rating in a research report on Sunday, December 4th. Finally, Zacks Investment Research lowered shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 18th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $21.00.
In other Stemline Therapeutics news, insider David Gionco sold 3,593 shares of the stock in a transaction on Thursday, January 19th. The shares were sold at an average price of $11.46, for a total transaction of $41,175.78. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Kenneth Hoberman sold 9,110 shares of the stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $13.82, for a total transaction of $125,900.20. The disclosure for this sale can be found here. Corporate insiders own 16.70% of the company’s stock.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Want to see what other hedge funds are holding STML? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stemline Therapeutics, Inc. (NASDAQ:STML).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/j-goldman-co-lp-invests-2139000-in-stemline-therapeutics-inc-stml/1661037.html
Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.